Bridge Biotherapeutics Yönetim

Yönetim kriter kontrolleri 0/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

James Jungkue Lee

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	9.2%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Bridge Biotherapeutics' (KOSDAQ:288330) Cash Burn Situation

Feb 17

A Look At Bridge Biotherapeutics' (KOSDAQ:288330) Share Price Returns

Dec 23

CEO

James Jungkue Lee

no data

Görev süresi

Mr. James Jungkue Lee serves as Chief Executive Officer and Director at Bridge Biotherapeutics Inc. Mr. Lee founded Bridge Biotherapeutics, Inc. in 2015. Mr. James Jungkue Lee served as the Vice President...

Bridge Biotherapeutics Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Bridge Biotherapeutics, Inc., Annual General Meeting, Mar 26, 2024

Insufficient new directors

Insufficient new directors

Bridge Biotherapeutics, Inc., Annual General Meeting, Mar 30, 2021

Recent updates

New major risk - Shareholder dilution

Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis

Bridge Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of KRW 21.5364 billion.

New major risk - Share price stability

Full year 2023 earnings released: ₩2,059 loss per share (vs ₩2,102 loss in FY 2022)

New major risk - Revenue size

Bridge Biotherapeutics, Inc., Annual General Meeting, Mar 26, 2024

Bridge Biotherapeutics, Inc. announced that it has received KRW 1.99999872 billion in funding

Third quarter 2023 earnings released: ₩387 loss per share (vs ₩540 loss in 3Q 2022)

Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC

Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis

New minor risk - Shareholder dilution

Bridge Biotherapeutics, Inc. announced that it has received KRW 5.9999904 billion in funding

New minor risk - Share price stability

New minor risk - Market cap size

Insufficient new directors

Bridge Biotherapeutics, Inc. Initiates Phase 2 Clinical Trial of BBT-877 in Patients with Idiopathic Pulmonary Fibrosis

Bridge Biotherapeutics, Inc. Presents Non-Clinical Study Results for 2 IPF Candidates at the IPF Summit 2022

Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877

Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022

Insufficient new directors

Bridge Biotherapeutics, Inc. Presents Preclinical Data of BBT-207 at the AACR Annual Meeting 2022

Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis

Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for Bbt-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site

Bridge Biotherapeutics, Inc., Annual General Meeting, Mar 30, 2021

Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 4.999995 billion in funding from LegoChem Biosciences, Inc.

New 90-day high: ₩16,700

Here's Why We're Not Too Worried About Bridge Biotherapeutics' (KOSDAQ:288330) Cash Burn Situation

New 90-day high: ₩15,800

A Look At Bridge Biotherapeutics' (KOSDAQ:288330) Share Price Returns

Bridge Biotherapeutics, Inc. Announces Termination of Collaboration and License Agreement with Boehringer Ingelheim

Bridge Biotherapeutics Announces Detailed Plans for the Phase 2A Study of BBT-401

New 90-day high - ₩47,300

New 90-day low - ₩37,950

CEO

Görev süresi